Latest Industry Press Releases More...

We bring you the latest pharmaceutical press releases in our pharmaceutical Industry Press Releases section to help our clients gain great exposure on industry happenings. Know about mergers, deals, technology release, and other information first hand from press conferences of industry leaders with our Global pharmaceuticals Industry Press Releases.

OncBioMune Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today announces the signing of a work order with leading Contract Research Organization, Theradex Oncology (“Theradex”), detailing the scope to be provided by Theradex for a clinical trial…

Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for rare diseases, today announced positive results from the Phase 2 PREVENT study. PREVENT is a multi-center, placebo-controlled study investigating the safety and durability of effect of 28-day dosing of subcutaneous (SC) avexitide (formerly known as exendin 9-39)…

Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today announced that its IND application for a combination therapy of IBI308 (Sintilimab, an anti-PD-1 monoclonal antibody) and IBI305 (a biosimilar to the recombinant humanized anti-VEGF monoclonal antibody bevacizumab), has been approved by the…

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase…

Sutro Biopharma, Inc., has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001 for the treatment of multiple myeloma. STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74, a protein highly expressed in B-cell malignancies such as multiple myeloma. "There is…

The U.S. Food and Drug Administration today approved ID CORE XT, a molecular-based assay used in blood transfusion medicine to help determine blood compatibility. The assay can be used to determine blood donor and patient non-ABO red blood cell (RBC) types. ID CORE XT is the second molecular assay approved…

Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology, today announces it has raised USD 53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised USD…

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several planned updates to the Phase 2 portion of its ongoing MANIFEST study, an open-label Phase 1/2 clinical trial of its BET inhibitor CPI-0610 in MF. MANIFEST is evaluating CPI-0610,…

NeuroVive Pharmaceutical AB today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA). KL1333 is a first-in-class NAD+modulator in clinical development for chronic oral…

Topix Pharmaceuticals, Inc., a leader in micro-branded skin care innovations, announces the launch of its Backbar Line, a collection of 10 professional products that empower physicians to utilize their own micro-branded line in the treatment room and provide patients with the same branded regimen for at home use. The comprehensive…

loader